SU5416 (Semaxanib): Selective VEGFR2 Tyrosine Kinase Inhibitor for Angiogenesis and Immune Modulation

Executive Summary: SU5416 (Semaxanib) is a small molecule VEGFR2 (Flk-1/KDR) inhibitor that blocks VEGF-induced angiogenesis, inhibiting endothelial cell proliferation and tumor vascularization at low micromolar concentrations (APExBIO). It demonstrates high selectivity, sparing FGF-driven pathways by over 1000-fold. SU5416 is also an aryl hydrocarbon receptor agonist, enabling immune modulation via IDO induction and regulatory T cell differentiation. In vivo, SU5416 (A3847) exhibits robust tumor growth inhibition in xenograft mouse models, with validated dosing and low toxicity. This article synthesizes key molecular mechanisms, benchmarks, and integration strategies for reliable use in angiogenesis and immune research (Lemay et al., 2025).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a key process in tumor growth, metastasis, and chronic inflammation (Lemay et al., 2025). Vascular endothelial growth factor (VEGF) signaling through VEGFR2 (Flk-1/KDR) is the principal driver of endothelial cell proliferation and neovascularization in both physiological and pathological contexts. Dysregulated VEGF pathways contribute to cancer progression, pulmonary arterial hypertension, and autoimmune disorders. Small molecule inhibition of VEGFR2 provides a targeted approach to suppress aberrant angiogenesis without broadly affecting other tyrosine kinase pathways. SU5416 (Semaxanib) achieves this by competitively inhibiting the ATP-binding domain of VEGFR2, halting downstream phosphorylation events essential for angiogenic signaling (related article—this article extends previous coverage by detailing immune modulation and integration in non-cancer models).

Mechanism of Action of SU5416 (Semaxanib)

SU5416 binds selectively to the ATP-binding pocket of VEGFR2 (Flk-1/KDR), preventing receptor autophosphorylation and subsequent activation of downstream kinases. Its half-maximal inhibitory concentration (IC₅₀) against VEGFR2 is 1.23 μM, with minimal off-target activity on fibroblast growth factor (FGF)-driven mitogenesis (>1000-fold selectivity) (APExBIO). This blocks endothelial cell proliferation, migration, and tube formation—key steps in angiogenesis. Additionally, SU5416 acts as an agonist at the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor. AHR activation by SU5416 upregulates indoleamine 2,3-dioxygenase (IDO), which modulates tryptophan metabolism and fosters regulatory T cell differentiation, leading to immunosuppressive effects relevant in cancer, transplantation, and autoimmunity (see also: this article updates with new immune benchmarks).

Evidence & Benchmarks

• SU5416 inhibits VEGFR2 autophosphorylation with IC₅₀ = 1.23 μM in cell-free kinase assays (APExBIO).
• Demonstrates >1000-fold selectivity for VEGF-driven vs. FGF-driven mitogenesis in HUVECs (APExBIO).
• Suppresses endothelial cell proliferation and tube formation in vitro at concentrations as low as 0.01–10 μM (JNJ-38877605.com—this article provides updated dosing and workflow tips).
• Inhibits tumor growth in mouse xenograft models at 3–25 mg/kg/day; no mortality observed during 3–4 week regimens (Lemay et al., 2025).
• Induces IDO and regulatory T cell differentiation via AHR activation, supporting immune modulation applications (Fusion-Glycoprotein.com—this article clarifies mechanistic immune endpoints).
• Soluble in DMSO at ≥11.9 mg/mL; insoluble in water and ethanol (APExBIO).
• Stable when stored in DMSO below -20°C; degradation observed at room temperature or with repeated freeze-thaw cycles (APExBIO).

Applications, Limits & Misconceptions

SU5416 (Semaxanib) is widely used in oncology, vascular biology, and immune modulation research. Its primary application is the inhibition of VEGF-induced angiogenesis in vitro and in vivo. By blocking VEGFR2, SU5416 suppresses neovascularization in solid tumors and model systems of pathological angiogenesis. The compound's role as an AHR agonist allows investigation of immune tolerance, regulatory T cell biology, and IDO-mediated immune suppression. SU5416 is not approved for therapeutic use in humans and is intended solely for laboratory research. Its selectivity profile limits off-target effects, but does not guarantee efficacy in all angiogenesis-driven conditions.

Common Pitfalls or Misconceptions

• SU5416 does not inhibit non-VEGFR tyrosine kinases at relevant concentrations; effects on unrelated kinases are negligible (APExBIO).
• It is not effective in models where angiogenesis is driven by FGF or PDGF rather than VEGF.
• SU5416 is not soluble in water or ethanol; DMSO is required for stock solution preparation (APExBIO).
• Prolonged exposure to light or repeated freeze-thaw cycles can degrade compound potency.
• Use in humans or for diagnosis/therapy is not authorized; research use only.

Workflow Integration & Parameters

For in vitro studies, SU5416 is typically used at 0.01–100 μM in DMSO-based stock solutions. Experimental endpoints include endothelial cell proliferation, migration, and tube formation assays. For in vivo xenograft studies, doses of 3–25 mg/kg/day (intraperitoneal or subcutaneous) have shown robust tumor growth inhibition over 3–4 weeks without observed toxicity (Lemay et al., 2025). Solutions should be freshly prepared and stored at below -20°C. The product is shipped as a solid (C₁₅H₁₄N₂O, MW 238.28), and is available as SKU A3847 from APExBIO (product page).

For additional troubleshooting, see this guide, which provides scenario-driven solutions for cytotoxicity and viability assays—this piece further elaborates on immune endpoints and protocol stability.

Conclusion & Outlook

SU5416 (Semaxanib) is a validated, selective VEGFR2 inhibitor enabling robust inhibition of VEGF-driven angiogenesis and tumor growth in preclinical models. Its dual activity as an AHR agonist expands its use to immune modulation and tolerance studies. When used according to validated protocols and storage conditions, SU5416 provides reproducible results in angiogenesis and immunology research. Ongoing studies are clarifying its utility in complex disease models beyond oncology, including autoimmunity and transplantation. For detailed protocols and sourcing, refer to the APExBIO SU5416 (A3847) product page.